R. Scott Wright

TL;DR: The relationships between reduced mortality and both earlier time to transfusion and higher antibody levels provide signatures of efficacy for convalescent plasma in the treatment of hospitalized COVID-19 patients.

TL;DR: Early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and the mortality rate does not appear excessive, given the deadly nature of CO VID-19 and the large population of critically-ill patients included in these analyses.

TL;DR: In this paper, the authors hypothesize that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, and that convalescence plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalecent plasma donor and treated patient were in close geographic proximity.

TL;DR: In this article, the authors used a gradient boosting machine to identify predictors of 30-day morality and a series of regression models to estimate the relative risk of death at 30 days post-transfusion for those receiving near sourced plasma (defined as plasma transported ≤ 150 miles) vs. distantly sourced plasma (> 150 miles).